Home > About Primary Immunodeficiency (PI) > Diagnosis

PI Diagnosis

Types and Causes of PI1,2

There are more than 350 genetic disorders that can cause your immune system to not work like it should. Some of the more common types of PI include selective IgA deficiency, common variable immune deficiency (CVID), X-linked agammaglobulinemia (XLA), and severe combined immunodeficiency (SCID).

PI is different from secondary immunodeficiencies, which are caused by other conditions (such as diseases or consequences of certain types of medications), whereas PI is caused by a defect in the immune system, and can be inherited.

There's relief with diagnosis.

Charlotte, diagnosed at age 38

How Common Is PI?2-7

Primary immunodeficiency was once thought to be very rare, but now it is considered more common. As PI awareness with physicians continues to grow, more people are getting diagnosed. In fact, PI can affect 1 in over 1,200 people which is nearly as common as cystic fibrosis.

PI can impact anyone at any age and of either gender, but more than half (51%) of patients with PI are not diagnosed until >30 years of age. According to the 2007 IDF survey, a PI diagnosis can take about 12.4 years from the time symptoms begin.

One of the reasons it can be difficult to diagnose is because many PIs present as routine infections (i.e. sinus infections or pneumonia) and go undetected in multiple healthcare settings. PI is often mistaken for a variety of diseases/infections from skin rashes to diarrhea to noninfectious conditions such as allergies.

Testing for PI2

When testing for PI, doctors will typically ask about your family history and do a physical exam. They may order blood tests to check if your red and white blood cells, antibodies, and immune system are working properly. These tests are important for your doctor to confirm a diagnosis of PI.

If you have been diagnosed, these tests help determine which type of PI you may have. Once the tests are complete, and the PI diagnosis is confirmed, your doctor will discuss the different treatment options available and work with you to identify the treatment option that best meets your medical needs and personal preferences.

References: 1. Picard C, Gaspar HB, Al-Herz W, et al. International union of immunological societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity. J Clin Immunol. 2018;38(1):96-128. 2. Blaese RM, Bonilla FA, Stiehm ER, Younger ME, eds. Patient & Family Handbook for Primary Immunodeficiency Diseases. 5th ed. Towson, MD: Immune Deficiency Foundation; 2013. 3. Mirtajani SB, Farnia P, Hassanzad M, Ghanavi J, Farnia P, Velayati AA. Geographical distribution of cystic fibrosis; The past 70 years of data analyzis. Biomed Biotechnol Res J. 2017;1:105-12. 4. About Primary Immunodeficiencies. Immune Deficiency Foundation website. https://primaryimmune.org/about-primary-immunodeficiencies/. Accessed June 12, 2019. 5. Immune Deficiency Foundation. Primary Immunodeficiency Diseases in America: 2007 The Third National Survey of Patients. Prepared by Abt. SRBI, Inc. May 2009. 6. de Vries E, Driessen G. Educational paper: primary immunodeficiencies in children: a diagnostic challenge. Eur J Pediatr. 2011;170(2):169-177. 7. Modell V, Gee B, Lewis DB, et al. Global study of primary immunodeficiency diseases (PI) - diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res. 2011; 51(1):61-70.

Gammagard Liquid MyIgCoPayCard Program Terms and Conditions

This manufacturer's coupon program is not valid for prescriptions reimbursed, in whole or in part, by Medicaid, Medicare, Medigap, VA, DoD, TRICARE, or any other federal or state healthcare programs, including state pharmaceutical assistance programs, and where prohibited by the health insurance provider or by law

Shire's MyIgCoPayCard program provides a maximum total benefit of $5,000 for eligible out-of-pocket costs and expires 12 months from date of activation. Eligible costs include deductible, copayment, and co-insurance costs for eligible Shire IG (Immunoglobulin) products. Non-medication expenses, such as ancillary supplies or administration-related costs, are not eligible.

To be eligible, patients must: 1. be starting or receiving treatment with (and have current prescription for) an eligible Shire IG product with an ICD-10 for a diagnosis of Primary Immunodeficiency; and 2. have commercial insurance that covers medication costs for prescribed Shire IG product and allows for CoPay assistance; and 3. be two (2) years old or older.

Acceptance of this offer must be consistent with the terms of benefits provided by patient's health insurance provider.

Offer limited to one card per person and may not be combined with any other coupon, discount, prescription savings card, rebate, free trial, patient assistance, or other offer.

This program is only valid for residents of the United States.

Shire reserves the right to change or discontinue this program at any time without notice.

This is not health insurance.

-----

Add to patient instructions:

If your insurance situation changes, it is your responsibility to notify MyIgSource's CoPay assistance program.


© 2017 Shire. All rights reserved.

SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates. Gammagard Liquid is a trademark or registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.

S30515 04/17

Please expand for Indication and Important Safety Information.

IMPORTANT SAFETY INFORMATION

What is the most important information that I should know about GAMMAGARD LIQUID?

GAMMAGARD LIQUID can cause the following serious reactions: severe allergic reactions causing difficulty in breathing or skin rashes; decreased kidney function or kidney failure; blood clots in the heart, brain, lungs or elsewhere in the body; severe headache, drowsiness, fever, painful eye movements, or nausea and vomiting; dark colored urine, swelling, fatigue, or difficulty breathing.